Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis

NCT03900325 is registered in ClinicalTrials.gov with Bird Rock Bio, Inc. as lead sponsor.

NCT NCT03900325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03900325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis
Lead sponsor
Bird Rock Bio, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
August 1, 2019
Completion date
April 30, 2020
Enrollment
6 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic gastroparesis